Sana Biotechnology (SANA) Capital Expenditures (2020 - 2026)

Sana Biotechnology has reported Capital Expenditures for 7 years, with the latest figure at $288000.0 in Q1 2026.

• Quarterly Capital Expenditures rose 111.76% year-over-year to $288000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 113.23% YoY) and the FY2025 annual result came in at $938000.0, changed N/A from the prior year.
• Capital Expenditures fell to $288000.0 in Q1 2026 per SANA's latest filing, from $873000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $8.5 million in Q2 2022 and troughed at -$9.5 million in Q3 2022.
• A 5-year average of $701823.5 and a median of $136000.0 in 2025 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2022 and 2024: Capital Expenditures jumped 3207.0% in 2022, then tumbled 2141.7% in 2024.
• Over 5 years, Capital Expenditures stood at -$1.2 million in 2022, then surged by 396.6% to $3.5 million in 2023, then tumbled by 107.4% to -$258000.0 in 2024, then surged by 438.37% to $873000.0 in 2025, then sank by 67.01% to $288000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $288000.0, $873000.0, and $65000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.